Getting the New Migraine Drugs Covered: Step Therapy, Documented Failures, and the Bridge Programs

Migraine care has a modern absurdity: a class of drugs designed specifically for the disease (the CGRP inhibitors: Aimovig, Emgality, Ajovy, Vyepti for prevention; Nurtec, Ubrelvy, Zavzpret for attacks; Qulipta for both), which the American Headache Society now calls first-line for prevention, sitting behind insurance walls that require you to fail older, cheaper drugs first. It's the step-therapy treadmill at its purest, and the players who get through are the ones whose failures are written down. Here's the whole path.

Know the gate you're walking through

• Acute CGRPs (Nurtec ODT, Ubrelvy, Zavzpret): typical criteria are a migraine diagnosis plus documented inadequate response or intolerance to two triptans, or a contraindication to triptans entirely (cardiovascular disease makes triptans off-limits, which is itself a qualifying route many people don't realize they're on).
• Preventive CGRPs (Aimovig, Emgality, Ajovy, Qulipta, Vyepti): typically 4+ migraine days a month plus failure of two older preventive classes (beta blockers, topiramate, amitriptyline, candesartan) at adequate doses for adequate trials, commonly 6 to 8 weeks each.
• Reauthorization usually wants evidence it's working: reduced monthly migraine days, documented in follow-ups. The headache diary that got you approved is also what keeps you approved.
• Botox for chronic migraine (15+ headache days/month) runs a parallel track with its own criteria, and failing it is itself a qualifying step for some CGRP authorizations.

The documentation sprint that unlocks everything

1. Reconstruct the history in one visit: book time with your prescriber specifically to get every past medication into the chart with dates, doses, duration, and why it stopped (didn't work, side effects, contraindication). Pharmacy records and old charts fill memory gaps.
2. Keep the headache diary in evidence-grade form: dates, duration, severity, medications taken, function lost ("left work," "dark room 6 hours"). Monthly migraine days is the metric every criterion and reauthorization turns on; the invisible-illness documentation rules apply wholesale.
3. Make the PA submission answer the plan's own checklist: ask the insurer for the specific criteria (they'll read them to you), then make sure the prescriber's submission addresses each element by name. Generic submissions generate generic denials.
4. Denied anyway? Peer-to-peer review, then formal appeal, attaching the AHS first-line position statement and, if the plan's migraine rules are harsher than its comparable medical-drug rules, the parity vocabulary. A headache specialist's letter moves these; if you're fighting alone with a generalist PCP, a referral to headache medicine upgrades the whole campaign.

Paying during and after the fight

• Commercial insurance: use the manufacturer copay cards (every CGRP brand has one), which routinely drop copays to $0 to $10 and can bridge supply while the prior auth processes. The Medicare/Medicaid prohibition applies as always.
• Medicare: no copay cards, but the Part D out-of-pocket cap contains the worst case, tier exceptions exist, and manufacturer patient-assistance programs serve income-qualified Medicare patients with free drug.
• Cash bridges: some gepants have direct-pay programs, and GoodRx-style pricing occasionally beats a high brand tier; check before paying any quoted brand price.
• Don't abandon the generics reflexively: triptans work well for many people at generic prices, and the step-therapy trial (done properly, with a real dose, documented) is sometimes just... effective treatment. The fight is for the people the old drugs genuinely failed.